Investor Presentation IIR Conference Sydney

NZX Announcement

TruScreen Investor Presentation to
Independent Investment Research Conference


11 April 2019, Sydney - Real time cervical cancer screening technology company
TruScreen (NZX:TRU or “The Company”) presentation to institutional and retail
investors at the inaugural Coffee Microcaps conference is attached.

Hosted by Independent Investment Research, the conference brings together some of
Australia’s best ASX listed microcap companies and potential investors, with TruScreen
the only NZX Company presenting.

- ENDS -

For more information visit www.TruScreen.com or contact:

TruScreen Investors
Martin Dillon Investor Relations
CEO TruScreen Phone: +61 2 9237 2805
martindillion@truscreen.com Truscreen@we-buchan.com


About TruScreen:
Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen-
ultra-video/

TruScreen’s real time cervical cancer technology utilises a digital wand which is placed
on the surface of the cervix to measure electrical and optical signals from the
surrounding tissue. A sophisticated proprietary algorithm framework distinguishes
between normal and abnormal (cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor
(SUS) is used for each patient to protect against cross-infection.

For more information, visit our website at www.truscreen.com

Investor
Presentation
March 2019
(NZX:TRU)

BUSINESS MODEL
•NZD 166M
addressable market
p.a.
1
•Sale of SUS =
sustainable annuity
revenue
Distributors target:
•Public hospitals
•Private hospitals
•Public health
initiatives
•Governments
•Non-Government
Organisations
TruScreen device
Single Use Sensors (SUS)
TRUSCREENEND CUSTOMERS
1
Based on TruScreenachieving 5 per cent market share of developing markets’ cervical cancer screening age population screened once every three years
2

INVESTMENT SUMMARY
Only device of its type –CE Mark
approved for primary screening
Commercial stage cervical cancer
screening technology
Clinically-validated &
well-positioned for developing
nations
Significant opportunity in developing
nations:
NZD 166M addressable market p.a.
3
At TruScreen we are building our device, experiencing sales momentum in key markets through a
global distribution model and growing year on year.

CERVICAL CANCER AROUND THE WORLD
AFRICA
226M
INDIA
302M
MEXICO
31M
Fourth most
common cancer
worldwide
LATIN
AMERICA
120M
RUSSIA
44M
CHINA
401M
Screening age population
1BN+ women of
screening age in
developing nations
85% of cases occur
in developing
nations
90% of deaths occur
in developing
nations
Ref: Based on U.S Central Intelligence Agency (CIA) World Factbook
MIDDLE
EAST
70M
4

CORPORATE AND FINANCIAL OVERVIEW
Sales growth
175%
Snapshot
(YOY growth -against March 2019 estimate)
TruScreen distributor
network
31
countries
SUS sold
150,000
TruScreen devices
sold
268
TRUSCREEN OVERVIEW (NZD)
Market cap$34.M
Share price$0.16(as at 28 February 2019)
Cash position$1.3M(as at 28 February 2019)
Significant
shareholders
Directors and management hold 28.9%
Consolidated Nominees 13.62%
Browns Island Holdings Ltd 9.22%
WaitaraTrustees Limited 7.67%
5

KEY FINANCIALS
NZD (millions)
FY19
Forecast
FY18
Actual
FY17
Actual
FY16
Actual
% Change
FY19/FY18
Revenue3.02.21.41.8+36%
Sales2.20.80.60.5+175%
EBITDA(3.1)(3.6)(3.0)(1.3)+14%
Net Assets11.011.614.314.1-
Cash and Cash
Equivalents
1.21.23.72.3-
FINANCIAL DATA
6

CERVICAL CANCER IS A MAJOR PUBLIC HEALTH ISSUE
•Current vaccine programs only cover HPV types
that cause 70% of cervical cancer
•Some countries scaling back HPV vaccines (e.g.
Japan)
•At least 80 years away from cervical cancer
elimination
•Screening guidelines: every 2-5 years
•85% of cervical cancer cases
•Do not have HPV vaccination programs
•No or minimal screening programs
•Limited labinfrastructure
•Limited diagnostictechnicians
DEVELOPING NATIONSDEVELOPED NATIONS
Better screening solutions for cervical cancer are needed in developing nations.
TruScreen fulfils this market need.
7

HOW IT WORKS
•Low electrical charge and light examines the cervix’s surface
•Uses algorithm to determine if cervix tissue is normal or
abnormal
TRUSCREEN VS OTHER SCREENING METHODS
Patients
Painless
Non-Invasive
Real-time results
Clinics
Objective readings
Minimal training
Cost effective
Single visit
Portable
Patients
Repeat visit
Scraping ofcervix
Clinics
Widely varying accuracy
Human error
Labour intensive
Long wait times
(days/weeks/months)
Technology
Vaccinesdon’t cover all
HPV types
Technology
User-friendly
Accurate readings
TRUSCREEN
OTHER
Charging station
TruScreen
Device
Single Use Sensor
(SUS)
8

COMMERCIAL STRATEGY
•Lack of lab infrastructure
•High prevalence ofHPV &
cervical cancer
•Governments investing in
women’s health
•Market need for portable,
accurate screening
technology
Build awareness
•Key Opinion Leaders
engagement
•Medical conferences​
•Clinical trials/studies
Strong sales momentum
•Sales H1 FY 19 > Total Sales
FY18
•Annuity revenue with SUS
reorders
Global distribution
•31 countries
•Pilot public healthinitiatives
in key markets
Research and Development
•Second generation device in
market
TARGETING DEVELOPING
NATIONS
MARKET ENTRY &
DEVELOPMENT
SUCCESS SO FAR
Expand footprint ​
•Local distributorstrategy
•Public health initiatives
•Partnerships with Non-
Government Organisations and
Government agencies
Technology transfer to key
markets
1
Based on SUS sales x screening age population
9

World’s biggest cervical
cancer market
(Screening age population:
400M)
71% of TruScreen sales
Initial distribution
agreement signed 2014
KEY MARKET: CHINA
Screening programs
•Various programs run by Central, State and Municipal governments, plus charities and major
state owned enterprises (e.g. Sinopec)
Market presence
•CDC (Centre for Disease Control) –12,000 women in pilot program –report due 2019
•COGA (Chinese Obstetricians & Gynaecologists Association) –screen 20,000 women in
public hospitals. Commenced Nov 2018, completion in 2020
•Xinjiang province -Western China (190 hospitals)
•Hospital usage of SUS: 150/m, with some using 1,000/m
Pipeline
•KOL support from COGA
•CDC program: Adoption in 3,000 women and children’s hospitals
•COGA program: Open up 200 public hospitals in 2019
•Xinjiang: 100 devices in 2019 and 190 in 2020 for government screening program -up to 2M
women every two years
•Installation in 50 ‘Breast and Cervical Cancer Centres’ in rural areas in 2019
•‘Medical Checkup’ centres-target at least 50 in 2019, and then expand
FACTS
10

KEY MARKETS: MEXICO AND AFRICA
11
•Split between Central Government and State Health Secretariats, Public
Insurance Agencies (ISSTE and IMES), armed forces and state-owned
monopolies e.g. Pemex
•New Central Government is conducting an overhaul of the National
Health administration and TruScreen will adjust plans to suit
•Installed in National Cancer Institute
•Installed in 'Health Train', ISSTE, Pemex and state-owned hospitals
•Central and State Government Health Secretariats
•National health insurer, ISSTE –500,000 pap test p.a. (Installed in 4 ISSTE
hospitals)
•National oil monopoly, PEMEX –60,000 pap tests p.a. (installed in 2
Pemex hospitals)
•Private lab and clinic chains
MEXICO
Screening Programs
Market Presence
Pipeline
AFRICA
•National Aids Council of Zimbabwe
•Use thisfor both Government and NGO support for other projects in East
Africa –Malawi and Mozambique submission being prepared
•Collaborating with DYSIS Medical and WISAP Medical Technology GmbH
•TruScreen selected Zimbabwe NAC programs for AIDS affected women
•Ministry of Health supported aid application to use TruScreen for a
national screening program
•Evaluated by National Aids Council of Zimbabwe
•Target East and Southern African countries with high HIV prevalence
Market Presence
Pipeline
Screening Programs

KEY MARKETS: RUSSIA AND INDIA
12
•No Central Government screening programs​
•State and Municipal Governments conduct ad hoc programs
•Distribution agreement withIMSystemswith initial orders in Feb 2019​
•Advanced payment of USD $250k
•Evaluated by ROSZDRAVNADZOR(Russia FDA)
•Targeting State Government Health Systems, starting with St Petersburg
•Private clinics and hospitals
•Split between Central Government and State Health Agencies and
government institutions –Armed Forces,State Rail et al.
•Central Government has mandated that all women over 25 be screened
for breast and cervicalcancer
•Engaged major distributor (KLAB) –700 employees
•Commenced marketing in four states –Delhi NCR, Madhya Pradesh,
Haryana and Maharashtra
•All India Institute of Medical Science (AIIMS)
•Central and State Governments (aim for inclusion in the 2019 National
Ministry of HealthBudget)
•Armed Forces Hospitals and Armed Forces Medical Research Centre
•Major Private Hospital Groups (e.g.Fortis, Apollo)
RUSSIAINDIA
Screening Programs
Market Presence
Pipeline
Screening Programs
Market Presence
Pipeline

Market development
Deepen market penetration via:
Endorsement from Key Opinion Leaders
Government adoption
Major screening programmes
Build funding organisation support for TruScreen
programmes
Enhance distribution networks
Manufacturing
Expand capability
SUS manufacturing technology transfer
Build annuity revenues
Transition early adopters to commercial users
Further regulatory approvals and clinical trials
UPCOMING MILESTONES
13

EXPERIENCED EXECUTIVE TEAM
•Founding CEO of TruScreen
since initial
commercialisation
•12 years in sales and
marketing of women’s
health products
•Chartered accountant with
30 years financial
management and leadership
experience
•Company Secretary for
TruScreen
•Qualified gynaecologist
•Extensive experience in
China, and East Asia
•Oversees distributors,
market evaluation and
clinical trials
MARTIN DILLON
CEO
GUY ROBERTSON
CFO
DR JERRY TAN
GM INTERNATIONAL
BUSINESS
DEVELOPMENT
Medical Advisory Board Experts in gynaecologyand
vulvovaginal disease
Board of Directors with extensive commercial experience
14
Executive team supported by a team of 7 key personnel with significant scientific and engineering experience
TONY HO
CHAIRMAN
•Non-executive chairman of
Greenland Minerals (ASX: GGG)
and Bioxyne(ASX:BXN)
•NED and Chairman of the audit
committee of Credit Intelligence
(ASX:CI1)
•Past NED of Hastings Technology
Metals (ASX:HAS) and Brazin
(ASX:BRZ)

FY18 Goals and Strategic Progress
Tony HoMartin DillonGuy Robertson
ChairmanChief Executive OfficerChief Financial Officer
Investor relations enquiries: truscreen@we-buchan.com
CONTACT
www.TruScreen.com
15

FY18 Goals and Strategic Progress
APPENDIX
16

TRUSCREEN PERFORMANCE
Interim results RHW (2017): Excellent. 93% Negative Predictive Value
Interimresults 6 teaching hospitals in China (2018): T1 Sensitivity: 90.4%; Specificity: 75.3%
TruScreen1 at Guadalajara (2016)Sensitivity to CIN2+ 78%Specificity 64%
TruScreen1 at Singer et al (2003)Sensitivity to CIN2+ 70%Specificity 80%
TruScreen1 atLi Xia et al in China
(2011)
Sensitivity to CIN2+ 81.7%Specificity 79.6%
TruScreen1at Guangdong China
(2010)
Sensitivity to CIN2+ 78.8%Specificity 74.4%
TruScreen1 in Shandong China
(2010)
Sensitivity to CIN2+ 75%Specificity 85%
CLINIC DATA
PAP and HPV in TruScreen’smarkets –Sensitivity to CIN2+
Guadalajara (2016)HPV DNA 56%PAP 36%
TruScreen1in Hainan China (2011)PAP 71.3%
TruScreen1at Guangdong China
(2010)
PAP 42.2%
TruScreen1 in Shandong China
(2010)
PAP 43%
17

COMMERCIALISATION JOURNEY AND MILESTONES
2018 -Dec
Migration to NZX
2018 -Jul
Commence
large scale pilot
with China CDC
and COGA
2018 -Oct
523%sales
growth in H1
2018 -Aug
HIV African
Initiative
2018 -Jul
New Australian
production facility
fully operational
2017 -Dec
CFDA approval for
second generation
device
2017 -Mar
Gained Indian
market
2015 -Sep
Approval for
Mexico market
2019 –Feb
New distribution
agreement in
Russia
2014 -Nov
Listing on NZAX
2016 -Apr
CE Mark for second
generation device
18

Disclaimers
This presentation should be viewed in conjunction with TruScreen’sFinancial Statements for the 12 monthsto 31 March 2018 and the accompanying NZX release.
The information presented is a snapshot and does not contain supporting information necessary to make an investment decision.It is not intended to act as a
recommendation to acquire TruScreenshares. There can be no assurancethatactual outcomes will notmaterially differ from the forward looking statements presented.
A number of important factors could cause actual results or performanceto differ materiallyfromtheforward-looking statements.Theforward-looking statements are
based on information available toTruScreen as at thedateof this presentation. Except as requiredby law (including the NZAX ListingRules), TruScreen undertakes no
obligation to provide any additional orupdatedinformation whether asa result of new information, future events or results or otherwise. TruScreen, its advisers,
affiliates,related bodiescorporate, directors, officers,partners, employees and agents make no representation or warranty, express or implied, as to thecurrency, accuracy,
reliabilityor completeness ofinformation in this presentation.
19